oru.sePublikationer
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high-level antimicrobial resistance: potential treatment option for gonorrhea?
WHO Collaborating Centre for Gonorrhoea and other STIs, National Reference Laboratory for Pathogenic Neisseria, Department of Laboratory Medicine, Microbiology, Örebro University Hospital, Örebro, Sweden.
Cempra Pharmaceuticals, Inc., Chapel Hill NC, United States.
National Institute of Infectious Diseases, Tokyo, Japan.
Department of Microbiological Surveillance and Research, Statens Serum Institut, Copenhagen, Denmark.
Show others and affiliations
2012 (English)In: Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, E-ISSN 1098-6596, Vol. 56, no 5, 2739-2742 p.Article in journal (Refereed) Published
Abstract [en]

Gonorrhea may become untreatable, and new treatment options are essential. We investigated the in vitro activity of the first fluoroketolide, solithromycin. Clinical Neisseria gonorrhoeae isolates and reference strains (n = 246), including the two extensively drug-resistant strains H041 and F89 and additional isolates with clinical cephalosporin resistance and multidrug resistance, were examined. The activity of solithromycin was mainly superior to that of other antimicrobials (n = 10) currently or previously recommended for gonorrhea treatment. Solithromycin might be an effective treatment option for gonorrhea.

Place, publisher, year, edition, pages
American Society for Microbiology , 2012. Vol. 56, no 5, 2739-2742 p.
National Category
Pharmacology and Toxicology Microbiology in the medical area
Identifiers
URN: urn:nbn:se:oru:diva-58670DOI: 10.1128/AAC.00036-12ISI: 000302790400072PubMedID: 22354296Scopus ID: 2-s2.0-84860176932OAI: oai:DiVA.org:oru-58670DiVA: diva2:1121610
Note

Funding Agencies:

Örebro County Council Research Committee  

Foundation for Medical Research at Örebro University Hospital, Sweden  

Cempra Pharmaceuticals, Inc., Chapel Hill, NC 

Available from: 2017-07-12 Created: 2017-07-12 Last updated: 2017-09-14Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedScopus

Authority records BETA

Golparian, DanielUnemo, Magnus

Search in DiVA

By author/editor
Golparian, DanielUnemo, Magnus
By organisation
Örebro University Hospital
In the same journal
Antimicrobial Agents and Chemotherapy
Pharmacology and ToxicologyMicrobiology in the medical area

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 5 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf